NCT06910111 - CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction) | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Atherosclerotic Disease

Interventions

DEVICE

Polyglucosamine

The treatment will continue for 12 months administering a customized Polyglucosamine (formoline AtheroGuard) (twice/day) before the two main meals for a total of 4 tabs/day (each tab consists of 750 mg). Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months

DEVICE

Placebo

2x 2 Placebo tablets The treatment will continue for 12 months administering Placebo (twice/day) before the two main meals for a total of 4 tabs/day. Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months

Trial Locations (3)

56126

Pisa University Hospital - Clinical Research Unit, Pisa

66100

University Gabriele d'Annunzio Chieti - Pescara, Chieti

06129

S. Maria della Misericordia Hospital, Perugia